Analyst Price Target is $4.00
▲ +277.36% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Lexicon Pharmaceuticals in the last 3 months. The average price target is $4.00, with a high forecast of $5.00 and a low forecast of $3.00. The average price target represents a 277.36% upside from the last price of $1.06.
Current Consensus is
The current consensus among 1 polled investment analysts is to hold stock in Lexicon Pharmaceuticals. This Hold consensus rating has held steady for over two years.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.